Merck plans trial of sac-TMT combo with Keytruda in lung cancer

Trial Startsac-TMTKeytrudaPositive

AI Analysis

Summary

Merck announced plans to conduct a trial testing its experimental antibody-drug conjugate sac-TMT in combination with Keytruda in lung cancer, representing a strategy to enhance its blockbuster immunotherapy.

Clinical Trial Data

Importance:5/10

Sentiment:

0.40

oncologyimmunotherapyantibody-drug conjugatecombination therapylung cancer

Related Companies

$MRK

Read the original article

Published by Endpoints News on August 4, 2026 5:30 PM

Read Original